IRVINE, Calif., July 31, 2026
enVVeno Medical Corporation reported its second quarter 2026 financial results, highlighting significant progress toward commercialization of its first-in-class enVVe® System, a minimally invasive, non-surgical replacement venous valve designed to treat patients with severe deep chronic venous insufficiency (CVI). During the quarter, the company achieved a major regulatory milestone by receiving U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) approval to initiate the TAVVE® pivotal clinical trial, marking the first FDA-approved U.S. pivotal study evaluating a transcatheter replacement venous valve for severe deep CVI. The company expects patient enrollment to begin during the second half of 2026, with the study planned to enroll approximately 230 patients across up to 40 U.S. clinical sites, positioning enVVe as a potential breakthrough treatment for nearly 3 million U.S. patients who currently have limited therapeutic options.
FDA IDE Approval Clears Path for Landmark TAVVE Pivotal Study
The FDA IDE approval represents a major milestone for enVVeno Medical, enabling clinical evaluation of the enVVe System, a bioprosthetic transcatheter replacement venous valve developed to restore proper venous valve function without open surgery. Severe deep chronic venous insufficiency is a progressive vascular disease caused by damaged venous valves that can result in debilitating leg swelling, pain, skin changes, and venous ulcers. Unlike conventional therapies that primarily manage symptoms, the enVVe System is designed to replace dysfunctional venous valves through a minimally invasive catheter-based procedure, potentially addressing the underlying cause of the disease. Alongside the regulatory achievement, the company also strengthened its intellectual property portfolio with a new U.S. patent covering key components of the device, reinforcing its competitive position as it advances toward pivotal clinical development and potential future commercialization.
Strong Financial Position Supports Clinical Development Through 2027
enVVeno Medical ended the second quarter with approximately $21.5 million in cash and investments, including $2.8 million in cash and cash equivalents and $18.7 million in short-term investments, which management believes will support operations into the third quarter of 2027. The company reported a net loss of $3.6 million for the quarter, compared with $6.7 million during the same period last year, representing an approximately 46% year-over-year reduction while continuing to prioritize clinical development. Quarterly cash burn totaled $3.4 million, in line with company expectations, although management anticipates spending will increase to $4–5 million per quarter as enrollment begins in the TAVVE pivotal trial. According to Chief Executive Officer Rob Berman, the company’s primary focus for the remainder of 2026 is activating clinical sites, initiating patient enrollment, and advancing the pivotal study that could redefine treatment for severe deep CVI.
Advertisement
enVVe Aims to Transform Treatment for Chronic Venous Disease
The enVVe System represents a novel approach to treating deep chronic venous insufficiency, offering the potential to become the first FDA-approved transcatheter replacement venous valve for patients with severe disease. By combining minimally invasive delivery, bioprosthetic tissue valve technology, and catheter-based implantation, the device seeks to provide a durable alternative to conservative management while avoiding invasive surgery. Successful completion of the TAVVE pivotal study could establish a new treatment paradigm for patients suffering from advanced venous disease, an area with significant unmet clinical need. With FDA IDE approval secured, a strengthened patent portfolio, and funding expected to support development into 2027, enVVeno Medical is positioned to advance one of the most innovative cardiovascular medical device programs currently progressing through late-stage clinical development.
Source: enVVeno Medical,press release
